All In Biotech

Drug Trial Radar · NCT01308580

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen

Last checked: Nov 19, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,200 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,200

Actual

Start

Apr 2011

Primary completion

Aug 2015

Study completion Aug 2015

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Mar 4, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To demonstrate the non inferiority in term of overall survival (OS) of Cabazitaxel 20 mg/m² (Arm A) versus Cabazitaxel 25 mg/m² (Arm B) in combination with prednisone in participants with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. Secondary Objectives: * To evaluate safety in the 2 treatment arms and to assess if Cabazitaxel 20 mg/m² was better tolerated than Cabazitaxel 25 mg/m². * To compare efficacy of Cabazitaxel at 20 mg/m² and 25 mg/m² for: * Progression Free Survival (PFS) defined as the first occurrence of any of the following events: tumor progression per Response Evaluation Criteria In Solid Tumors (RECIST), prostate-specific antigen (PSA) progression, pain progression or death due to any cause; * PSA Progression; * Pain progression; * Tumor response in participants with measurable disease (RECIST 1.1); * PSA response; * Pain response in participants with stable pain at baseline. * To compare Health-related Quality of Life (HRQoL). * To assess the pharmacokinetics and pharmacogenomics of Cabazitaxel.

Conditions

  • Prostate Cancer

Interventions

  • Cabazitaxel (XRP6258)Drug

    Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous

  • Prednisone (or Prednisolone)Drug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From baseline up to death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)

Locations

172 sites in 22 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840002

    Muscle Shoals, Alabama

  • Investigational Site Number 840004

    Hot Springs, Arkansas

  • Investigational Site Number 840008

    Anaheim, California

  • Investigational Site Number 840010

    La Jolla, California

  • Investigational Site Number 840001

    San Bernardino, California

  • Investigational Site Number 840021

    Stamford, Connecticut

  • Investigational Site Number 840023

    Jacksonville, Florida

  • Investigational Site Number 840013

    Lakeland, Florida

  • Investigational Site Number 840003

    Port Saint Lucie, Florida

  • Investigational Site Number 840007

    New Orleans, Louisiana

  • Investigational Site Number 840014

    Baltimore, Maryland

  • Investigational Site Number 840005

    Rockville, Maryland

  • Investigational Site Number 840017

    Saint Louis Park, Minnesota

  • Investigational Site Number 840011

    Jackson, Mississippi

  • Investigational Site Number 840016

    Lincoln, Nebraska

  • Investigational Site Number 840015

    East Orange, New Jersey

  • Investigational Site Number 840024

    Raleigh, North Carolina

  • Investigational Site Number 840020

    Akron, Ohio

  • Investigational Site Number 840006

    Pawtucket, Rhode Island

  • Investigational Site Number 840025

    Chattanooga, Tennessee

  • Investigational Site Number 840012

    Corpus Christi, Texas

  • Investigational Site Number 032002

    Buenos Aires, Argentina

  • Investigational Site Number 032001

    Rosario, Argentina

  • Investigational Site Number 032003

    Salta, Argentina

  • Investigational Site Number 032004

    Santa Fe, Argentina

  • Investigational Site Number 036014

    Adelaide, Australia

  • Investigational Site Number 036013

    Bankstown, Australia

  • Investigational Site Number 036010

    Box Hill, Australia

  • Investigational Site Number 036012

    Camperdown, Australia

  • Investigational Site Number 036008

    Coffs Harbour, Australia

  • Investigational Site Number 036001

    Concord, Australia

  • Investigational Site Number 036015

    Elizabeth Vale, Australia

  • Investigational Site Number 036009

    Fitzroy, Australia

  • Investigational Site Number 036007

    Garran, Australia

  • Investigational Site Number 036005

    Heidelberg West, Australia

  • Investigational Site Number 036002

    Malvern, Australia

  • Investigational Site Number 036006

    South Brisbane, Australia

  • Investigational Site Number 036016

    Subiaco, Australia

  • Investigational Site Number 036003

    Wahroonga, Australia

  • Investigational Site Number 036004

    Wodonga, Australia

Showing 40 of 172 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.